Association between oxidant/antioxidant markers and proteinuria in type 2 diabetes: Results in 142 patients

Journal of Nephrology

Volumn 22, Issue 6, 2009, Pages 733-738

  Rashidi, Armin ^a   Nakhjavani, Manouchehr ^a   Esteghamati, Alireza ^a   Asgarani, Firuzeh ^a   Khalilzadeh, Omid ^a   Abbasi, Mehrshad ^a   Safari, Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes; MDA; Oxidative stress; Oxidized LDL; Proteinuria; SOD

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; CHOLESTEROL; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE DURATION; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PROTEINURIA; SEX DIFFERENCE; SMOKING HABIT;

AGED; ANTIOXIDANTS; BIOLOGICAL MARKERS; CREATININE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IRAN; KIDNEY; LIPOPROTEINS, LDL; LOGISTIC MODELS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDANTS; OXIDATIVE STRESS; PROTEINURIA; RISK ASSESSMENT; RISK FACTORS; SUPEROXIDE DISMUTASE;

EID: 72149091442     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Shimada K, Mokuno H, Matsunaga E, et al. Predictive value of circulating oxidized LDL for cardiac events in type 2 diabetic patients with coronary artery disease. Diabetes Care. 2004;27:843-844.
2. O'Brien SF, Watts GF, Playford DA, Burke V, O'Neal DN, Best JD. Low-density lipoprotein size, high-density lipoprotein concentration, and endothelial dysfunction in non-insulin-dependent diabetes. Diabet Med. 1997;4:974-978.
3. Woodman RJ, Watts GF, Playford DA, Best JD, Chan DC. Oxidized LDL and small LDL particle size are independently predictive of a selective defect in microcirculatory endothelial function in type 2 diabetes. Diabetes Obes Metab. 2005;7:612-617.
4. Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 2005;15:316-328.
5. Stralin P, Karlsson K, Johansson BO, Marklund SL. The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterioscler Thromb Vasc Biol. 1995;15:2032-2036.
6. Genuth S, Alberti KG, Bennett P, et al; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-3167.
7. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
8. Toshima S, Hasegawa A, Kurabayashi M, et al. Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol. 2000;20:2243-2247.
9. Adachi T, Ohta H, Yamada H, Futenma A, Kato K, Hirano K. Quantitative analysis of extracellular-superoxide dismutase in serum and urine by ELISA with monoclonal antibody. Clin Chim Acta. 1992;212:89-102.
10. Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by new colorimetric method. Clin Chim Acta. 1978;90:37-43.
11. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes. 2008;57:1446-1454.
12. Coughlan MT, Mibus AL, Forbes JM. Oxidative stress and advanced glycation in diabetic nephropathy. Ann N Y Acad Sci. 2008;1126:190-193.
13. Kasahara J, Kobayashi K, Maeshima Y, et al. Clinical significance of serum oxidized low-density lipoprotein/beta2-glycoprotein I complexes in patients with chronic renal diseases. Nephron Clin Pract. 2004;98:15-24.
14. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis. 2000;35:852-862.
15. Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC. Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant. 1998;13:2281-2287.
16. Alabakovska SB, Todorova BB, Labudovic DD, Tosheska KN. LDL and HDL subclass distribution in patients with end-stage renal diseases. Clin Biochem. 2002;35:211-216.
17. Massy ZA, Nguyen-Khoa T. Oxidative stress and chronic renal failure: markers and management. J Nephrol. 2002;15:336-341.
18. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65:1009-1016.
19. Tsuzura S, Ikeda Y, Suehiro T, et al. Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism. 2004;53:297-302.
20. Ujihara N, Sakka Y, Takeda M, et al. Association between plasma oxidized low-density lipoprotein and diabetic nephropathy. Diabetes Res Clin Pract. 2002;58:109-114.
21. Kimura F, Hasegawa G, Obayashi H, et al. Serum extracellular superoxide dismutase in patients with type 2 diabetes: relationship to the development of micro- and macrovascular complications. Diabetes Care. 2003;26:1246-1250.
22. Nozik-Grayck E, Suliman HB, Piantadosi CA. Extracellular superoxide dismutase. Int J Biochem Cell Biol. 2005;37:2466-2471.
23. Fattman CL, Schaefer LM, Oury TD. Extracellular superoxide dismutase in biology and medicine. Free Radic Biol Med. 2003;35:236-256.
24. Adachi T, Yamada H, Futenma A, Kato K, Hirano K. Heparin-induced release of extracellular-superoxide dismutase form (V) to plasma. J Biochem. 1995;117:586-590.
25. Tamsma JT, van den Born J, Bruijn JA, et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia. 1994;37:313-320.
26. Adachi T, Nakamura M, Yamada H, Futenma A, Kato K, Hirano K. Quantitative and qualitative changes of extracellular-superoxide dismutase in patients with various diseases. Clin Chim Acta. 1994;229:123-131.
27. Karlsson K, Sandstrom J, Edlund A, Edlund T, Marklund SL. Pharmacokinetics of extracellular-superoxide dismutase in the vascular system. Free Radic Biol Med. 1993;14:185-190.
28. Bhatia S, Shukla R, Venkata Madhu S, Kaur Gambhir J, Madhava Prabhu K. Antioxidant status, lipid peroxidation and nitric oxide end products in patients of type 2 diabetes mellitus with nephropathy. Clin Biochem. 2003;36:557-562.
29. Ozdemir G, Ozden M, Maral H, Kuskay S, Cetinalp P, Tarkun I. Malondialdehyde, glutathione, glutathione peroxidase and homocysteine levels in type 2 diabetic patients with and without microalbuminuria. Ann Clin Biochem. 2005;42:99-104.
30. Apakkan Aksun S, Ozmen B, Ozmen D, et al. Serum and urinary nitric oxide in Type 2 diabetes with or without microalbuminuria: relation to glomerular hyperfiltration. J Diabetes Complications. 2003;17:343-348.